Frequently Asked Questions
North America dominates the human leukocyte antigens (HLAs) typing transplant diagnostics services market in terms of market share and market revenue.
The growth rate of the human leukocyte antigens (HLAs) typing transplant diagnostics services market is 9.45% by 2029.
Upsurge in the public-private funding for target research activities & rising number of solid organ and stem cell transplantation procedures are the growth drivers of the human leukocyte antigens (HLAs) typing transplant diagnostics services market.
Product and services, application, end-user, and technology are the factors on which the human leukocyte antigens (HLAs) typing transplant diagnostics services market research is based.
Major companies in the human leukocyte antigens (HLAs) typing transplant diagnostics services market report are Thermo Fisher Scientific Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN, Immucor, Inc., Bio-Rad Laboratories, Inc., Luminex Corporation., CareDx, Inc., GenDx, Voden Medical Instruments S.p.a., TBG Diagnostics Limited, ProImmune Ltd, Pacific Biosciences of California, Inc, Omixon Inc., omicX, MC Diagnostics Ltd, Integrated Gulf Biosystems, InGen and Hologic, Inc., among others.
